- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01473290
Probiotic Therapy in Preventing Gastrointestinal Complications in Patients Undergoing Chemotherapy and Pelvic Radiation Therapy
A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in the Prevention of Acute Enteritis in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy
RATIONALE: Probiotic therapy may reduce or prevent gastrointestinal complications in patients undergoing chemotherapy and pelvic radiation therapy.
PURPOSE: This randomized phase III trial is studying how well probiotic therapy works in preventing gastrointestinal complications in patients undergoing chemotherapy and pelvic radiation therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- To determine whether live freeze-dried lactic acid bacteria probiotic (VSL#3®) is effective in reducing the acute treatment-related bowel function disturbances, as measured by the FACIT-D diarrhea subscale score in patients receiving concurrent chemotherapy and pelvic RT as adjuvant or primary treatment for malignancy.
Secondary
- To determine whether VSL#3® can reduce chronic treatment-related bowel dysfunction following completion of therapy.
- To examine whether VSL#3® appears to have an impact on disease-free survival.
- To bank blood products for future studies. (exploratory)
- To characterize changes in the fecal microbiota and examine for correlation with treatment assignment and symptom scores. (exploratory)
OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to site of primary tumor (rectum/anus vs other), history of anterior resection of the rectum (yes vs no), total planned cumulative dose (including boost of external-beam radiotherapy [RT] or brachytherapy) (4,500-5,350 cGy vs > 5,350 cGy), and use of intensity-modulated RT [IMRT] for pelvic RT (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive live freeze-dried lactic acid bacteria probiotic (VSL#3®) orally (PO) 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
- Arm II: Patients receive placebo PO 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
Patients self-report symptoms using the FACIT-D, PBFQ, PRO-CTCAE, and Uniscale/fatigue weekly during RT, for 2 weeks after completion of RT, and at 12 months following the completion of RT.
Blood and stool samples may be collected from some patients for correlative studies.
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Current diagnosis of cancer that supports the use of continuous definitive or adjuvant external-beam radiotherapy (RT) to the pelvis to a minimum dose of 4,500 cGy with the following parameters:
The pelvis must be encompassed by the planned RT fields
- The superior border may not lie inferior to the most inferior aspect of the sacroiliac joints
- Portions of the rectum may have special blocking, depending upon disease site
The total prescription dose must lie between 4,500-5,350 cGy (inclusive)
- A boost to primary tumor or tumor bed may be planned
Planned treatment is to be given 4-5 times per week on a one- treatment-per-day basis
- The daily prescribed dose must lie between 170-210 cGy (inclusive) per day
- No planned split-course RT
- No proton RT
- Will receive concurrent administration of chemotherapy (fluorouracil, capecitabine, cisplatin, oxaliplatin, carboplatin, and/or mitomycin C) during pelvic RT
- No current or prior metastases beyond regional lymph nodes
PATIENT CHARACTERISTICS:
- ECOG performance status (PS) of 0, 1, or 2
- Life expectancy ≥ 6 months
- Able to complete questionnaire(s) by themselves or with assistance
- Not pregnant or nursing
- Negative pregnancy test done ≤ 7 days prior to registration, for women of childbearing potential only
- Fertile patients must use effective contraception
- Hemoglobin > 10.0 g/dL
- White blood cells (WBC) > 3,500/mm³
- Absolute neutrophil count (ANC) > 1,500/mm³
- Platelet count > 100,000/mm³
- Willing to abstain from ingestion of yogurt products and/or any product containing probiotics during study drug treatment
- No known allergy to a probiotic preparation
- No history of inflammatory bowel disease
- No ≥ grade 3 diarrhea, ≥ grade 3 rectal bleeding, abdominal cramping, or incontinence of stool ≤ 7 days prior to registration
- No medical condition that may interfere with ability to receive protocol treatment
- No history of gastrointestinal or genitourinary obstruction or porphyria
- No history of irritable bowel syndrome (IBS)
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior abdominal-perineal resection, Hartmann procedure, or other surgical procedure leaving the patient without a functioning rectum
- No planned use of leucovorin
- No prior pelvic RT
- No use of probiotics ≤ 2 weeks prior to registration
- No use of antibiotics ≤ 3 days prior to registration
- No planned continuous antibiotic treatment during RT
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I
Patients receive live freeze-dried lactic acid bacteria probiotic (VSL#3®) orally (PO) 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
|
Given orally (PO)
|
Placebo Comparator: Arm II
Patients receive placebo PO 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
|
Given PO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average area under the curve (AUC) of the FACIT-D diarrhea subscale score assessed weekly during treatment and for two weeks following the completion of RT
Time Frame: Up to 12 months
|
Up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bowel function measures as assessed by the clinician using the CTCAE version 4 and as assessed by the PBFQ and the PRO-CTCAE
Time Frame: Up to 12 months
|
Up to 12 months
|
Psychometric evaluation of the reliability and validity of the FACIT-D diarrhea subscale, PBFQ, and PRO-CTCAE
Time Frame: Up to 12 months
|
Up to 12 months
|
Disease-free survival
Time Frame: Up to 12 months
|
Up to 12 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCCTG-N10CB
- NCI-2011-03636 (Registry Identifier: CTRP (Clinical Trials Reporting System))
- CDR0000716291 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatigue
-
Bakulev Scientific Center of Cardiovascular SurgeryFoundation for the Support of Physical Culture and Sports BECOME A CHAMPION; Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPIONNot yet recruitingEfficacy, Self | Fatigue, Mental | Fatigue; Muscle, Heart | Fatigue; CombatRussian Federation
-
Universita di VeronaUniversity of Southern CaliforniaCompletedDiet, Healthy | Fasting | Fatigue, Mental | Fatigue; Muscle, HeartItaly
-
University of ZurichRecruitingVocal FatigueSwitzerland
-
KU LeuvenCompleted
-
Société des Produits Nestlé (SPN)Maastricht University Medical CenterCompleted
-
University of Applied Sciences for Health Professions...University of Wisconsin, MilwaukeeCompleted
-
Taoyuan General HospitalCompleted
-
Alaa Yousri Mahmoud AtiaUnknownMuscle FatigueEgypt
-
University Hospital, Clermont-FerrandLaboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques...CompletedNeuromuscular FatigueFrance
-
Central Hospital, Nancy, FranceUniversity of Lorraine; Institut National de Recherche et de Sécurité, Nancy...Unknown
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States